Results of a phase I/II British Society of Bone Marrow Transplantation study on PCR-based pre-emptive therapy with valganciclovir or ganciclovir for active CMV infection following alemtuzumab-based reduced intensity allogeneic stem cell transplantation

Leukemia Research

Volumn 33, Issue 2, 2009, Pages 244-249

  Lim, Z Y ^a   Cook, G ^b   Johnson, P R ^c   Parker, Anne ^d   Zuckerman, M ^a   Marks, D ^e   Wiltshire, H ^f   Mufti, G J ^a   Pagliuca, A ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^c WESTERN GENERAL HOSPITAL   (United Kingdom)

^d GLASGOW ROYAL INFIRMARY   (United Kingdom)

^e BRISTOL ROYAL INFIRMARY   (United Kingdom)

^f ROCHE PRODUCTS LTD   (United Kingdom)

Author keywords

Allogeneic transplantation; CMV reactivation; Ganciclovir; Reduced intensity conditioning; Valganciclovir

Indexed keywords

ALEMTUZUMAB; BUSULFAN; FLUDARABINE; FOSCARNET; GANCICLOVIR; MELPHALAN; VALGANCICLOVIR; VIRUS DNA;

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; MACULOPAPULAR RASH; MALE; MEDICAL SOCIETY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REDUCED INTENSITY CONDITIONING; THROMBOCYTOPENIA; TREATMENT DURATION; VIRUS LOAD;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; GANCICLOVIR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MIDDLE AGED; POLYMERASE CHAIN REACTION; PREMEDICATION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIRAL LOAD;

EID: 56949092079     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.07.016     Document Type: Article

References (14)

1. Chakrabarti S., Mackinnon S., Chopra R., et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood 99 (2002) 4357-4363
2. Einsele H., Ehninger G., Hebart H., et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 86 (1995) 2815-2820
3. Goodrich J.M., Mori M., Gleaves C.A., et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med 325 (1991) 1601-1607
4. Winston D.J., Baden L.R., Gabriel D.A., et al. Pharmacokinetics of ganciclovir after oral valganciclovir versus intravenous ganciclovir in allogeneic stem cell transplant patients with graft-versus-host disease of the gastrointestinal tract. Biol Blood Marrow Transpl 12 (2006) 635-640
5. Schmidt G.M., Horak D.A., Niland J.C., Duncan S.R., Forman S.J., and Zaia J.A. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; The City of Hope-Stanford-Syntex CMV Study Group. N Engl J Med 324 (1991) 1005-1011
6. Einsele H., Reusser P., Bornhauser M., et al. Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation. Blood 107 (2006) 3002-3008
7. Kearns A.M., Turner A.J., Eltringham G.J., and Freeman R. Rapid detection and quantification of CMV DNA in urine using LightCycler-based real-time PCR. J Clin Virol 24 (2002) 131-134
8. Czock D., Scholle C., Rasche F.M., Schaarschmidt D., and Keller F. Pharmacokinetics of valganciclovir and ganciclovir in renal impairment. Clin Pharmacol Ther 72 (2002) 142-150
9. Wiltshire H., Paya C.V., Pescovitz M.D., et al. Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. Transplantation 79 (2005) 1477-1483
10. Shimoni A., and Nagler A. Non-myeloablative hematopoietic stem cell transplantation (NST) in the treatment of human malignancies: from animal models to clinical practice. Cancer Treat Res 110 (2002) 113-136
11. Gonzalez H., Vernant J.P., and Caumes E. Successful oral valganciclovir treatment of cytomegalovirus infection during Campath-1H therapy. Leukemia 19 (2005) 478
12. van der Heiden P.L., Kalpoe J.S., Barge R.M., Willemze R., Kroes A.C., and Schippers E.F. Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients. Bone Marrow Transpl 37 (2006) 693-698
13. Busca A., de Fabritiis P., Ghisetti V., et al. Oral valganciclovir as pre-emptive therapy for cytomegalovirus infection post allogeneic stem cell transplantation. Transpl Infect Dis 9 (2007) 102-107
14. Ayala E., Greene J., Sandin R., et al. Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transpl 37 (2006) 851-856